Biotech Stocks Soar on Positive Cancer Study Results
TL;DR
ImmunoGen's drug, Elahere, lowered the risk of disease progression or death by 35% in a specific group of patients with ovarian cancer, while Day One Biopharmaceuticals' drug, Tovarafenib, showed a 67% response rate in pediatric brain tumors. Replimune's skin cancer treatment showed a 37% response rate in melanoma patients. Gilead Sciences and Arcus Biosciences' lung cancer treatment showed a median of 9.3 to 9.9 months before worsening.
Topics:businesshealthcare#cancer-treatment#day-one-biopharmaceuticals#elahere#healthcare#immunogen#tovarafenib
- IMGN Stock: Why This Perfectly Rated Biotech Just Soared, Again Investor's Business Daily
- Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study Yahoo Finance
- Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC OncLive
- Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma Medpage Today
- ImmunoGen stock jumps on Elahere cancer data (NASDAQ:IMGN) Seeking Alpha
Want the full story? Read the original reporting
Read on Investor's Business Daily